UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 103

Sortiert nach

Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis

Leukemia, 2022-08, Vol.36 (8), p.2108-2120

2022

Link zum Volltext

Verfügbarkeit prüfen

Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors

Journal of clinical oncology, 2008-04, Vol.26 (10), p.1603-1610

2008

Link zum Volltext

Verfügbarkeit prüfen

Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor

Journal of clinical oncology, 2003-12, Vol.21 (23), p.4342-4349

2003

Link zum Volltext

Verfügbarkeit prüfen

Molecular and Clinical Analysis of Locally Advanced Dermatofibrosarcoma Protuberans Treated With Imatinib: Imatinib Target Exploration Consortium Study B2225

Journal of clinical oncology, 2005-02, Vol.23 (4), p.866-873

2005

Link zum Volltext

Verfügbarkeit prüfen

Clinical and Molecular Studies of the Effect of Imatinib on Advanced Aggressive Fibromatosis (desmoid tumor)

Journal of clinical oncology, 2006-03, Vol.24 (7), p.1195-1203

2006

Link zum Volltext

Verfügbarkeit prüfen

Prevalence of KIT Expression in Human Tumors

Journal of clinical oncology, 2004-11, Vol.22 (22), p.4514-4522

2004

Link zum Volltext

Verfügbarkeit prüfen

Phase II Study of Imatinib in Patients with Small Cell Lung Cancer

Clinical cancer research, 2003-12, Vol.9 (16), p.5880-5887

2003

Link zum Volltext

Verfügbarkeit prüfen

Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group

European journal of cancer (1990), 2002-09, Vol.38, p.S83-S87

2002

Link zum Volltext

Verfügbarkeit prüfen

Design and Development of a Reduced Form-Factor High Accuracy Three-Axis Teslameter

Electronics (Basel), 2019-03, Vol.8 (3), p.368

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract 378: Exploring intermittent dosing schedules for the Pan PI3K/mTor inhibitor PQR309

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.378-378

2016

Link zum Volltext

Verfügbarkeit prüfen

Management of malignant gastrointestinal stromal tumours

The lancet oncology, 2002-11, Vol.3 (11), p.655-664

2002

Link zum Volltext

Verfügbarkeit prüfen

Poster: MPN-395: Efficacy and Safety of ≤200 mg Avapritinib in Patients with Advanced Systemic Mastocytosis: Pooled Results from the Phase 1 EXPLORER and Interim Phase 2 PATHFINDER Studies

Clinical lymphoma, myeloma and leukemia, 2021-09, Vol.21, p.S233-S233

2021

Link zum Volltext

Verfügbarkeit prüfen

MPN-395: Efficacy and Safety of ≤200 mg Avapritinib in Patients with Advanced Systemic Mastocytosis: Pooled Results from the Phase 1 EXPLORER and Interim Phase 2 PATHFINDER Studies

Clinical lymphoma, myeloma and leukemia, 2021-09, Vol.21, p.S367-S368

2021

Link zum Volltext

Verfügbarkeit prüfen

Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor

Journal of clinical oncology, 2023-11, Vol.41 (31), p.4829-4836

2023

Link zum Volltext

Verfügbarkeit prüfen

High-accuracy teslameter with thin high-resolution three-axis Hall probe

Measurement : journal of the International Measurement Confederation, 2017-02, Vol.98, p.407-413

2017

Link zum Volltext

Verfügbarkeit prüfen

INNV-17. RESPONSE TO AVAPRITINIB IN A PEDIATRIC SPINAL CORD H3K27M-MUTANT GLIOMA PATIENT

Neuro-oncology (Charlottesville, Va.), 2021-11, Vol.23 (Supplement_6), p.vi108-vi108

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract 382: Concomitant administration of acid reducing agents can impact the pharmacokinetics of the balanced pan-PI3K and mTOR inhibitor PQR309

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.382-382

2016

Link zum Volltext

Verfügbarkeit prüfen

Population pharmacokinetics of PQR309, a dual PI3K/mTOR inhibitor in adult patients with advanced solid tumors

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e14101-e14101

2016

Link zum Volltext

Verfügbarkeit prüfen

Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal Tumor

The New England journal of medicine, 2001-04, Vol.344 (14), p.1052-1056

2001

Link zum Volltext

Verfügbarkeit prüfen

DIPG-60. Avapritinib for targeting PDGFRA in H3K27M – mutated diffuse midline glioma

Neuro-oncology (Charlottesville, Va.), 2022-06, Vol.24 (Supplement_1), p.i32-i32

2022

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

The Lancet (British edition), 2001-10, Vol.358 (9291), p.1421-1423

2001

Link zum Volltext

Verfügbarkeit prüfen

The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations

Blood, 2002-03, Vol.99 (5), p.1741-1744

2002

Link zum Volltext

Verfügbarkeit prüfen

DDDR-22. TRANSLATION OF THE PDGFRA/KIT INHIBITOR AVAPRITINIB FOR PEDIATRIC HIGH-GRADE GLIOMA

Neuro-oncology (Charlottesville, Va.), 2022-11, Vol.24 (Supplement_7), p.vii103-vii103

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 103

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(87)
Mit Volltextzugriff
(99)

Publikationsform

Artikel
(97)
Tagungsberichte
(6)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(53)
Life Sciences & Biomedicine
(41)
Humans
(28)
Biological And Medical Sciences
(20)
Medical Sciences
(20)
Female
(19)
Male
(17)
Oncology
(17)
Adult
(16)
Benzamides
(16)
Imatinib Mesylate
(16)
Middle Aged
(15)
Tumors
(14)
Pharmacology. Drug Treatments
(13)
Aged
(12)
Piperazines - Therapeutic Use
(12)
Pyrimidines - Therapeutic Use
(12)
Technology
(12)
Antineoplastic Agents - Therapeutic Use
(10)
Antineoplastic Agents
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis

Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors

Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor

Molecular and Clinical Analysis of Locally Advanced Dermatofibrosarcoma Protuberans Treated With Imatinib: Imatinib Target Exploration Consortium Study B2225

Clinical and Molecular Studies of the Effect of Imatinib on Advanced Aggressive Fibromatosis (desmoid tumor)

Prevalence of KIT Expression in Human Tumors

P1023: AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM): EFFICACY AND SAFETY ANALYSES FROM THE PHASE 2 PATHFINDER STUDY WITH 2‐YEAR FOLLOW‐UP

Phase II Study of Imatinib in Patients with Small Cell Lung Cancer

Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group

Design and Development of a Reduced Form-Factor High Accuracy Three-Axis Teslameter

Abstract 378: Exploring intermittent dosing schedules for the Pan PI3K/mTor inhibitor PQR309

Management of malignant gastrointestinal stromal tumours

First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)

Poster: MPN-395: Efficacy and Safety of ≤200 mg Avapritinib in Patients with Advanced Systemic Mastocytosis: Pooled Results from the Phase 1 EXPLORER and Interim Phase 2 PATHFINDER Studies

MPN-395: Efficacy and Safety of ≤200 mg Avapritinib in Patients with Advanced Systemic Mastocytosis: Pooled Results from the Phase 1 EXPLORER and Interim Phase 2 PATHFINDER Studies

Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor

High-accuracy teslameter with thin high-resolution three-axis Hall probe

INNV-17. RESPONSE TO AVAPRITINIB IN A PEDIATRIC SPINAL CORD H3K27M-MUTANT GLIOMA PATIENT

Abstract 382: Concomitant administration of acid reducing agents can impact the pharmacokinetics of the balanced pan-PI3K and mTOR inhibitor PQR309

Population pharmacokinetics of PQR309, a dual PI3K/mTOR inhibitor in adult patients with advanced solid tumors

Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal Tumor

DIPG-60. Avapritinib for targeting PDGFRA in H3K27M – mutated diffuse midline glioma

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations

DDDR-22. TRANSLATION OF THE PDGFRA/KIT INHIBITOR AVAPRITINIB FOR PEDIATRIC HIGH-GRADE GLIOMA

Suchergebnisse filtern